New Blood Test Predicts Onset of Alzheimer’s Disease
A newly cleared blood test offers a less invasive and more accessible method for detecting early signs of Alzheimer’s disease, potentially predicting symptom onset years in advance. The test measures levels of specific proteins in the blood to identify amyloid plaques, a hallmark of the disease, offering a crucial tool for early diagnosis and intervention.
Understanding Alzheimer’s Disease and Early Detection
Alzheimer’s disease is a progressive brain disorder that gradually destroys memory and thinking skills. It affects over 10% of individuals aged 65 and older, and that number is projected to double by 2050 1. Early detection is critical, as interventions are most effective when initiated before significant cognitive decline occurs.
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio Test
The U.S. Food and Drug Administration (FDA) cleared the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test in May 2025 1. This in vitro diagnostic device measures the levels of two key proteins in human plasma: pTau217 and β-amyloid 1-42. By calculating the ratio between these proteins, the test can indicate the presence of amyloid plaques in the brain, a primary indicator of Alzheimer’s disease.
Advantages Over Traditional Methods
Previously, detecting amyloid plaques required costly and time-consuming PET (positron emission tomography) brain scans, which similarly expose patients to radiation 1. The blood test offers a more accessible, affordable, and convenient alternative for early detection.
How the Test Works
The test is designed for adults aged 55 years and older who are exhibiting signs and symptoms of Alzheimer’s disease. Elevated levels of pTau217, in particular, have been strongly associated with Alzheimer’s pathology 4 and brain damage caused by the disease 2. The test aids doctors in determining the probable cause of a patient’s symptoms and findings.
Recent Research and Findings
Studies have demonstrated the promise of blood tests in predicting the onset of Alzheimer’s symptoms. Research has focused on the ptau217 protein, identifying its strong correlation with Alzheimer’s disease pathology 2. The Mayo Clinic also offers a test evaluating pTau217 levels in plasma for individuals with cognitive impairment 3.
Looking Ahead
The availability of this blood test represents a significant step forward in the fight against Alzheimer’s disease. Early and accurate diagnosis will enable earlier intervention, potentially slowing the progression of the disease and improving the quality of life for millions. Further research and development in this area are expected to refine diagnostic tools and pave the way for more effective treatments.